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Background: Routine annual influenza vaccination is primarily recommended for all persons aged 60 and above
and for people with underlying chronic conditions in Germany. Other countries have already adopted additional
childhood influenza immunisation programmes. The objective of this study is to determine the potential
epidemiological impact of implementing paediatric influenza vaccination using intranasally administered
live-attenuated influenza vaccine (LAIV) in Germany.
Methods: A deterministic age-structured model is used to simulate the population-level impact of different
vaccination strategies on the transmission dynamics of seasonal influenza in Germany. In our base-case analysis,
we estimate the effects of adding a LAIV-based immunisation programme targeting children 2 to 17 years of age
to the existing influenza vaccination policy. The data used in the model is based on published evidence
complemented by expert opinion.
Results: In our model, additional vaccination of children 2 to 17 years of age with LAIV leads to the prevention of
23.9 million influenza infections and nearly 16 million symptomatic influenza cases within 10 years. This reduction in
burden of disease is not restricted to children. About one third of all adult cases can indirectly be prevented by
LAIV immunisation of children.
Conclusions: Our results demonstrate that vaccinating children 2–17 years of age is likely associated with a
significant reduction in the burden of paediatric influenza. Furthermore, annual routine childhood vaccination
against seasonal influenza is expected to decrease the incidence of influenza among adults and older people due
to indirect effects of herd protection. In summary, our model provides data supporting the introduction of a
paediatric influenza immunisation programme in Germany.
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Viral airway infections due to influenza pose severe
health problems to humans, critically affecting individ-
uals of any age, especially those with underlying medical
conditions. Pandemic and seasonal influenza viruses are
a constant public health threat with substantial morbid-
ity and mortality worldwide. There is an increasing body
of evidence that documents the health and economic
burden of influenza in children [1-3]. Rates of illness are
highest among children, and influenza and its complica-
tions are responsible for significant healthcare resource
use. Especially in young children, hospitalization rates
from influenza and its complications are similar to those
seen among the elderly population [4-6]. About 40% of
all influenza cases, 24% of outpatient visits, 10% of
hospitalization days, and 27% of working days lost due
to influenza are caused by childhood influenza [7]. In
addition, children are the major vectors of influenza
transmission within households and communities [8-10],
resulting in additional burden of disease from secondary
transmission of influenza.
Immunisation provides an effective and efficient tool
to control the spread of influenza. Hence, influenza vac-
cination is widely recommended by international health
organizations, mostly targeting the elderly population
and people with underlying chronic conditions [11,12].
In 2012, the WHO Strategic Advisory Group of Experts
on immunization (SAGE) suggested that children up to
5 years of age should be considered as a target group for
annual influenza vaccination [13]. Several national guide-
lines recommend annual influenza immunisation for
children [14]. For instance, since 2010, the US Advisory
Committee on Immunization Practices (ACIP) has recom-
mended annual influenza vaccination for all persons aged
six months and above [11]. The UK’s Joint Committee on
Vaccination and Immunisation (JCVI) which advises the
UK government on vaccination policy, recently recom-
mended an extension to the current public influenza im-
munisation programme to include routine vaccination of
children aged 2 to less than 17 years [15]. However, in
most countries children do not receive influenza immun-
isation, although they are highly at risk for infections and
tend to spread them through the community [14].
In Europe, immunisation against influenza has been
mainly based on injectable trivalent inactivated influenza
vaccines (TIV), providing systemic immunity especially
in immunocompetent individuals with antecedent con-
tact with the virus. In 2012, intranasally administered
live-attenuated influenza vaccine (LAIV) has also be-
come available in Europe, offering superior immuno-
logical features and a better protection of children and
adolescents than TIV [16-19].
Understanding the modes of influenza transmission
and the possible impact of its prevention by vaccines iscrucial for physicians, policy makers, and patients in
order to better understand the value of influenza im-
munisation programmes. Based on a complex mathem-
atical model of seasonal influenza transmission and
prevention, this paper provides data on the potential
population-level impact of different influenza immunisa-
tion strategies in Germany. The main objective of this
study is to estimate the epidemiological consequences of
adding annual routine influenza immunisation for chil-
dren 2 to 17 years of age using the nasal spray vaccine
to the existing German influenza vaccination policy of
mostly vaccinating risk-groups.
Methods
To simulate the transmission of influenza in the German
population (82 million inhabitants in 2008), we have de-
veloped a deterministic transmission model based on
German demographic data using a basic reproduction
number (R0) of 1.6 [20,21]. Our model considers two
influenza strains (influenza A and B) which are transmit-
ted independently without cross-immunity. Transmission
dynamics and demographic changes are described by a
system of 4,426 differential equations (see Additional
file 1). All simulations start on September 1st, 1998 [21].
As the initial age distribution of immunity is unknown, all
simulations start with a fraction of 45% immune individ-
uals and are run in with TIV immunisation at current
age-specific coverage rates for 14 years before a 10 years
lasting evaluation phase begins. During the evaluation
phase, TIV immunisation of children is either continued
at current coverage rates (scenario 1) or it is replaced by
vaccination with LAIV at increased uptake levels (scenario
2) and subsequently the daily differences in influenza in-
fections and symptomatic cases between the two scenarios
are calculated. Model parameters are based on published
literature or rely on expert opinion elicited by use of the
Delphi method. The expert panel consisted of six experts
specialised in paediatrics, infectious diseases or pulmonol-
ogy. All participants of the expert panel were key opinion
leaders in their respective research areas and were
identified through relevant publications, involvement in
influenza-related research activities or research networks
on infectious respiratory diseases. Expert opinion was elic-
ited using a two round Delphi study and a final consensus
meeting. The questionnaires included questions on influ-
enza transmission dynamics, the course of disease and
German-specific treatment patterns. At the beginning of
the Delphi process, all panellists were provided with the
results of a systematic literature search on relevant param-
eters. After each round, the experts were provided with a
summary of the experts’ responses. The response rate for
both rounds was 100%. Finally, the results of the Delphi
survey were discussed with all experts at a consensus
meeting. When a consensus could not be reached among
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mates were calculated. Ethical approval was not required
for this study. Details of the simulation model are as
follows.
Transmission model
The model extends the general structure of the classic
SEIRS (susceptible-exposed-infectious-recovered-suscep-
tible) model by adding the state of maternal protection
(M) and two different classes of vaccine-induced im-
munity (VLAIV and VTIV) (see Figure 1). Adults are fur-
ther grouped into age cohorts and risk classes. Children
and adolescents are classified into several age groups
without risk differentiation. A fraction of 30% of all new-
born individuals is assumed to be protected by maternal
antibodies for an average duration of four months dur-
ing which they cannot be infected. After losing their ma-
ternal protection, children become susceptible (S) and
can successfully be vaccinated or infected. If they be-
come infected, they first pass through a latent period (E)
which lasts on average one day before they become con-
tagious (I). Following this latent phase, they recover on
average after 5 days and become immune [22]. Naturally
acquired immunity lasts on average for 6 years after in-
fection with influenza A and for 12 years after infection
with influenza B. These durations account for waning
memory of the immune system and the accumulation of
antigenic changes in the pathogens. In our transmission
model, we use the German POLYMOD contact matrix
which describes the mixing of the age groups [23]. The
transmission probability per contact is calculated such
that the largest eigenvalue of the next generation matrix
yields a basic reproduction number R0 = 1.6. FollowingM
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Figure 1 Model structure. Individuals are either born susceptible (S) or w
vaccination. Only susceptible individuals can successfully be vaccinated (VL
period (E) before becoming infectious (I) and finally become immune (R). In
vaccination) and become susceptible again.the recommendations of the expert panel, we have used
a value of 1.6 for the basic reproduction number. This
number lies within the range estimated as the variation
across influenza seasons and countries by Chowell et al.
[20] (0.9-2.1). Chowell et al. [20] have published a confi-
dence interval that ranges from 1.2 to 1.4. As we address
both influenza A subtypes as “strain A” and both influ-
enza B lineages as “strain B”, we have to use a higher
value for the basic reproduction number of these
“strains” than what would be needed for four (or even
more) independently transmitted virus types. The choice
of R0 = 1.6 led to a good fit to observed influenza inci-
dence (see model validation section). The resulting
contact rate is varied seasonally with a peak around
Christmas which is 43% higher than the baseline [21]. It
is further assumed that the whole population is exposed
to infection from abroad at a low constant “external in-
fection rate” which yields about 1 infection per 1,000
susceptible person years. A total of 66.9% of all infected
individuals develop symptoms [22]; their symptom state
is assumed not to alter the transmissibility of infection.
Demographic model
The population is structured in 96 age classes of one
year each (except for the last age class which contains all
individuals who are 95 years of age or older). People die
according to age-specific rates which were derived from
German 2008 data [24]. In order to keep these parame-
ters constant for all simulation years, we used the 2008
demographic distribution and mortality rates to back-
calculate the demographic distribution and birth rates of
earlier years (see Additional file 1 for details). The an-
nual numbers of births in later years were obtained byVLAIV
VTIV
ith maternal protection (M), which prevents infection and successful
AIV and VTIV) or infected. When infected, they pass through a latent
dividuals can completely lose their immunity (derived by infection or
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In the simulation model, births and deaths occur
throughout the year, but ageing steps are only performed
at the end of each simulation year, i.e. on September 1st,
mimicking the transition in German school classes (e.g.
“11 year old children” become “12 year old children” on
September 1st of each year) [21]. Adults are further
subdivided into people with “normal risk” and people
with “increased risk” due to underlying chronic disease
(see Table 1) [25].
Vaccination model
Vaccinations are performed annually from October 1st
to November 30th (official German recommendation),
whereby a constant number of individuals are vaccinated
on each day. Each individual can be only vaccinated
once per year, receiving either TIV or LAIV. Depending
on the type of vaccine and on the age and risk status of
the vaccinated individuals, a fraction of susceptible indi-
viduals becomes temporarily immune after vaccination
(see Table 2). The duration of vaccination-derived im-
munity depends on the type of vaccine: based on the
vaccine efficacy measured in the first and second trans-
mission season, an average duration of 2.8 years ofTable 1 Parameters of the transmission model
Parameter Description
R0 Basic reproduction number
z Amplitude of seasonal transmission
α Outside infection rate (per person per year)
DL Average duration of the latent period (days)
DI Average duration of the infectious period (days)
fK Symptomatic fraction of infected individuals
fmed Fraction of symptomatic cases who seek medical help (i.e. p
- children below 2 years of age
- children from 2 to 6 years of age
- children from 7 to 12 years of age
- juveniles from 13 to 17 years of age
- adults below 60 years of age without increased risk
- adults with increased risk or above 60 years of age
fR Immune fraction before initialising the simulations
m Fraction of newborns protected by maternal antibodies
DM Average duration of maternal protection (months)
D Að ÞR Average duration of naturally acquired immunity to influenz
D Bð ÞR Average duration of naturally acquired immunity to influenz
DTIV Average duration of TIV induced immunity (years)
DLAIV Average duration of LAIV induced immunity (years)
r18–44 Percentage of people from 18 to 44 years of age with eleva
r45–59 Percentage of people from 45 to 59 years of age with eleva
TIV trivalent inactivated influenza vaccine; LAIV live-attenuated influenza vaccine.immunity has been calculated for LAIV [18,19,26],
whereas TIV-induced immunity is assumed to be lost on
average after 0.7 years [19,27-29] (details for the calcula-
tions are given in the Additional file 1).
Vaccination scenarios
During the 14-years lasting run-in phase of the simula-
tions, only TIV is used. In the subsequent intervention
phase, the initial age-dependent administration of TIV is
either continued unchanged (scenario 1) or vaccination
of children from 2 to 17 years of age is replaced by im-
munisation with LAIV (scenario 2) whereby the vaccin-
ation coverage increases from the baseline value up to
50% in three annual steps [30,31].
Model validation
We validated our simulation model in four ways: First,
the simulated age distributions in the years 2010, 2015,
and 2020 are compared to demographic predictions of
the German Federal Statistical Office [32]. Second, the
incidence of infections of children and young adults is
compared with published observations [33,34]. Third,
the simulated number of physician visits due to
influenza is compared to influenza-attributed excessBase-case value Reference
1.6 Chowell et al. [20]; expert opinion
43% Vynnycky et al. [21]
0.001 Assumption
1 Carrat et al. [22]
5 Carrat et al. [22]
66.9% Carrat et al. [22]
hysician consultation)
60% Expert opinion
40% Expert opinion
30% Expert opinion
10% Expert opinion
20% Expert opinion
50% Expert opinion
45% Assumption
30% Assumption
4 Expert opinion
a A (years) 6 Vynnycky et al. [21]
a B (years) 12 Vynnycky et al. [21]
0.7 Assumption
2.8 Guided by Tam et al. [26]
ted risk 7.6% Fleming & Elliott [25]
ted risk 17.6% Fleming & Elliott [25]
Table 2 Vaccination parameters
Age class Vaccine
efficacya
Reference Vaccination coverage Reference
(initial value)Scenario 1 Scenario 2
TIV LAIV TIV TIV LAIV
1 year 11.0% N/A Vesikari et al. [41] 19.2% 19.2% — Blank et al. [30]
2 years 59.0% 80.0% Jefferson et al. [19]; Rohrer et al. [18] 19.2% 19.2% 22.4-50%b Blank et al. [30]
3-6 years 59.0% 80.0% Jefferson et al. [19]; Rohrer et al. [18] 22.4% N/A 22.4-50%b Blank et al. [30]
7-10 years 59.0% 80.0% Jefferson et al. [19]; Rohrer et al. [18] 23.6% N/A 23.6-50%b Blank et al. [30]
11-17 years 59.0% 80.0% Jefferson et al. [19]; Rohrer et al. [18] 11.0% N/A 11.0-50%b Blank et al. [30]
18-59 years, normal risk 68.0% N/A Monto et al. [29] 14.5% 14.5% N/A Blank et al. [30]
18-59 years, elevated risk 58.0% N/A Jefferson et al. [28] 29.8% 29.8% N/A Blank et al. [31]
60-64 years 58.0% N/A Jefferson et al. [28] 33.1% 33.1% N/A Blank et al. [31]
65-69 years 58.0% N/A Jefferson et al. [28] 47.6% 47.6% N/A Blank et al. [31]
70 years and over 58.0% N/A Jefferson et al. [28] 53.4% 53.4% N/A Blank et al. [31]
TIV trivalent inactivated influenza vaccine; LAIV live-attenuated influenza vaccine; N/A not applicable.
aVaccine efficacy determines the fraction of (previously susceptible) vaccinees who are immune due to vaccination at the peak of the following transmission
season (i.e. 100 days after vaccination).
bLAIV coverage increases in three annual steps from the initial to the final percentage.
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(RKI) [35]. Based on the results of the Delphi panel, we
assume that the following percentages of infected indi-
viduals seek medical care: 60% of children younger than
2 years of age, 40% of children from 2 to 6 years, 30% of
children from seven to 12 years, 10% of juveniles (13 to
17 years), 20% of otherwise healthy adults from 18 to
59 years, and 50% of elderly and adults with increased
risk. Using the same age classes as the RKI (i.e. 0–4, 5–
14, 15–34, 35–59, 60+), we calculate the annual number
of outpatient visits per 100,000 individuals for each year
of the second half of our initialization period (i.e., for
the years 2004 to 2011). Fourth, in order to check for
coding errors, the transmission model was coded twice
by two software developers who coded the simulations
independently: one software developer used JAVA and
solved the differential equation system numerically,
using the fourth-order Runge–Kutta method with auto-
matic step size control [36]. The other software devel-
oper used the programming languages C and Scilab
version 5.3 (an open-source analogue of MatLab),
employing the hybrid ODE solver “rkm9mkn” (Intel® Or-
dinary Differential Equation Solver Library) which auto-
matically chooses between an implicit and an explicit
method, depending on the results of a repetitive calcula-
tion of the Jacobi matrix of the differential equation sys-
tem. In the final validation, the resulting annual and
total numbers of infections and vaccinations were
compared.
Results
Validation results
The validation demonstrated good model fit in various
areas. The estimated incidence of infections of youngadults matched the published observations. Williams
et al. [33] showed that 10.6% of examined health care
workers and controls had a serologically confirmed in-
fluenza infection or an at least fourfold rise in influenza
antibody titre during the 2006/2007 influenza season in
Germany. In our simulation study, 4,098,465 infections
occur in the group of young healthy adults (18 to
59 years without increased risk) in the same time period.
Relating these infections to the group size of 42,284,307
individuals yields a simulated infection rate of 9.7%
which is similar to the observation of Williams et al.
[33]. Using the set of parameter values from Chowell
et al. [20] (Rp = 1.3; duration of the latent period = 1.9
days; duration of the infectious period = 4.1 days) instead
of our set of parameters would lead to an infection inci-
dence of 15.56% per year among young adults. Likewise,
using the set of parameter values from Pitman et al. [37]
(R0 = 1.8; duration of the latent period = 2 days; duration
of the infectious period = 2 days) would lead to an infec-
tion incidence of 12.69% per year for young adults which
is quite a bit higher than the observed infection inci-
dence in Germany.
Williams et al. [33] furthermore report that about 30%
of individuals with serologically confirmed influenza in-
fection did not report influenza-like symptoms, which
corresponds well to the 33.1% of asymptomatic infec-
tions which is assumed in our simulation study.
Since German data on childhood influenza infection
incidence is scarce, we used estimates from an inter-
national systematic review [34] to validate our simula-
tion results for children. Bueving et al. [34] included 28
studies and found a wide variation in the incidence of
laboratory-proven influenza illness ranging from 0 to
46% in children aged 0–19 years. However, only two of
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tions. These studies reported an average seasonal inci-
dence of 4.6% in children aged 0–19 years and 9.5% in
children < 5 years. Our model simulates an influenza ill-
ness incidence of 5.57% in children aged 0–19 years.
Figure 2 compares the simulated number of physician
visits before the introduction of LAIV immunisation to
data on estimated influenza-associated excess consulta-
tions published by the RKI [34]. Except for the age class
of the elderly, our simulation results are much lower
than the values reported by RKI. Our simulated age dis-
tribution corresponds very well to the official German
predictions, only the number of children and some of
the age classes of elderly are slightly lower in our simu-
lations than what is officially predicted (see Additional
file 1 for details).
The results of the internal model validation, using two
independent programming approaches, showed a nearly
perfect concordance of the simulation results obtained
with the two different software systems: for the chosen
set of parameters (which differed slightly from the pa-
rameters used in this publication), a total of about
96,500,000 infections occurred in scenario 1 in the total
simulation time of 24 years, yet the two programmes dif-
fered by less than 0.2 infections. Likewise, the total num-
ber of vaccinations deviated by less than a millionth of a
per cent.0
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Figure 2 Excess consultations per 100,000 per year. Grey bars represen
confidence intervals are estimates of influenza-associated excess consultatiBase-case analysis
Figure 3 shows the simulated dynamics of symptomatic
influenza cases. Due to the seasonal fluctuations in the
transmissibility of influenza and annual vaccination cam-
paigns, influenza transmission shows an expressed sea-
sonality with peaks at the end of February. During the
run-in phase, a percentage of children and adults receive
annual vaccination with TIV (scenario 1; light grey solid
curve). In the autumn of 2012, TIV immunisation of
children from 2 to 17 years is fully replaced by LAIV im-
munisation whereby the vaccination coverage is in-
creased in three annual steps up to its final value of 50%
(scenario 2; dark grey dashed curve). Figure 4 shows the
simulated total annual number of symptomatic influenza
cases in the 10-year evaluation phase. The left bar of
each pair shows the results of scenario 1 with TIV im-
munisation, the right bar of each pair shows those of
scenario 2 with LAIV immunisation of children.
Whereas cases decline only moderately in scenario 1,
they drop considerably in the first years of scenario 2
and increase again thereafter.
During the 10-year evaluation phase, a total of 58.9 mil-
lion infections occur in scenario 1 (37.9 million influenza
A infections, and 20.9 million influenza B infections). A
total of 23.9 million infections are prevented by additional
LAIV immunisation (13.7 million A, and 10.2 million B)
in scenario 2. Table 3 shows that nearly two thirds of40 45 50 55 60 65 70 75 80
e (years)
t outpatient physician visits simulated by the model, dots with 95%
ons published by the RKI.
050,000
100,000
150,000
200,000
250,000
300,000
350,000
400,000
450,000
1998 2000 2002 2004 2006 2008 2010 2012 2014 2016 2018 2020 2022
In
fe
ct
ed
 in
di
vi
du
al
s
Year
Figure 3 Simulated seasonal fluctuation in influenza infections. The light grey solid curve shows influenza A and B infections in scenario 1
where only TIV is used, the dark grey dashed curve shows those in scenario 2 where TIV immunisation of children 2 to 17 years old is replaced in
2012 by LAIV immunisation and where childhood vaccination coverage with LAIV is subsequently increased up to 50% in three annual steps.
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are prevented by LAIV vaccination. This reduction is not
restricted to children: about one third of all adult cases can
indirectly be prevented by LAIV immunisation of children.
Overall, LAIV vaccination prevents more than 40% of all
influenza infections and symptomatic cases in the German
population. When relating the number of 23.9 million pre-
vented infections and 16 million prevented symptomatic
cases to the additional 27.4 million vaccinations in scenario
2, it shows that on average 1.15 vaccinations prevent one
infection, or that 1.71 vaccinations prevent one symptom-
atic case (number needed to vaccinate, NNV).
Sensitivity analyses
In our base-case analysis, LAIV-induced immunity is as-
sumed to last much longer than TIV-induced immunity.0
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Figure 4 Annual average number of symptomatic influenza cases. Th
where only TIV is used, the right bar of each pair represents those in scena
in 2012 by LAIV immunisation and where childhood vaccination coverage
The lower parts of the bars correspond to the number of paediatric cases,
aged 18 years and above.When halving the duration of LAIV-induced immunity,
the number of prevented symptomatic influenza cases
decreases from 16 to 12 million within 10 years. Figure 5
compiles results of univariate sensitivity analyses where
key parameter values are modified individually whereas
all remaining parameter values are kept unchanged. The
fraction of infected individuals who become symptom-
atic is a parameter with a very high influence on the
difference of symptomatic cases between scenario 1 and
2. The duration of naturally acquired influenza A
immunity is also very influential. Due to the dominance
of influenza A cases, it has much more impact than
the duration of influenza B immunity. The basic
reproduction number determines the number of second-
ary cases and the duration of the infectious period deter-
mines the spread of the infection and, thus, theseYear
016 2017 2018 2019 2020 2021
e left bar of each pair shows symptomatic influenza cases in scenario 1
rio 2 where TIV immunisation of children 2 to 17 years old is replaced
with LAIV is subsequently increased up to 50% in three annual steps.
the upper parts of the bars indicate the number of cases in adults
Table 3 Simulated numbers of influenza vaccinations and outcomes in children and adults using base-case values
Vaccinations
and outcomesa
Children (0–17 years) Adults (18 years and over)
Scenario 1b Scenario 2c Difference Scenario 1b Scenario 2c Difference
Vaccinations
TIV 19,297,651 1,084,672 −18,212,979 180,955,563 180,955,563 0
LAIV 0 45,637,434 45,637,434 0 0 0
Total 19,297,651 46,722,106 27,424,455 180,955,563 180,955,563 0
Epidemiological outcomes
Infections 13,830,361 4,835,746 −8,994,615 (−65.0%) 45,033,115 30,122,649 −14,910,466 (−33.1%)
Symptomatic cases 9,252,511 3,235,114 −6,017,397 (−65.0%) 30,127,153 20,152,052 −9,975,101 (−33.1%)
TIV trivalent inactivated influenza vaccine; LAIV live-attenuated influenza vaccine.
aAll results are estimates for the 10-year evaluation period.
bScenario 1: TIV immunisation at current age-specific vaccination coverage.
cScenario 2: TIV immunisation of children 2 to 17 years of age is replaced by LAIV immunisation, with coverage increasing up to 50% in three annual steps.
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cine efficacy of LAIV complements the list of most influ-
ential factors.
In the base-case analysis, we have assumed that it will
be recommended to vaccinate children between 2 and
17 years of age with LAIV and that these children will
gradually increase their annual vaccination coverage
while children under 2 years of age continue to receive
TIV at the same level of uptake. The recommended vac-
cination scheme starts in 2012 with children receiving
either TIV or LAIV at the baseline coverage shown in
Table 2. In the following three years, LAIV coverage in-
creases up to 50%. In Figure 6, we modify many of these
assumptions: we change the maximum vaccination age
for children from 17 years to another age (shown at the
right hand side of the curves). We further assume that11,000,000
Duration of maternal protection (1-6 months)
Fraction of 18- to 59-year-olds with higher risk (± 50%)
Amplitude of seasonal fluctuation (20-60%)
Duration of the annual vaccination campaign (30-90 days)
External infection rate (0.0005-0.002/year)
Duration of the infectious period (3-7 days)
Basic reproduction number (1.3-2.4)
Efficacy of LAIV (± 10%)
Duration of naturally acquired influenza B immunity (8-16 years)
Fraction developing symptoms (± 20%)
Duration of immunity after vaccination with LAIV (1.4-5.6 years)
Duration of naturally acquired influenza A immunity (2-10 years)
Figure 5 Results of one-way sensitivity analyses. Each of the horizonta
parameter of the model across a given range on the number of symptoma
their base values. The dark grey bars represent the upper bound of the ran
cases are the difference of symptomatic influenza cases between scenario
constantly in scenario 1, whereas TIV immunisation in children 2 to 17 year
increasing up to 50% in three annual steps.the final vaccination coverage of these children will not
be 50%, but a value between 30 and 95% (given on the
horizontal axis). In Figure 6a, we assume that all chil-
dren receive TIV; children up to the maximum recom-
mended age increase their vaccination coverage; older
children are constantly vaccinated with the same cover-
age as in scenario 1. In Figure 6b, we assume that chil-
dren below 2 years of age receive TIV with increasing
coverage, children from 2 years to the maximum recom-
mended age receive LAIV with increasing coverage, and
older children receive TIV (at constant scenario 1 vac-
cination coverage). In Figure 6c, we assume that children
below 2 years of age receive TIV with increasing cover-
age, children from 2 years to the maximum recom-
mended age receive LAIV with increasing coverage, and
older children receive LAIV, but at the same constant15,000,000 19,000,000 23,000,000 27,000,000 31,000,000
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Figure 6 Results of two-way sensitivity analyses varying the vaccination coverage and the maximum vaccination age. These charts
show how many additional symptomatic influenza cases are prevented in scenario 2 during the 10-year evaluation period in Germany when
compared to scenario 1. In scenario 1, TIV is used for all age classes with constant age-specific vaccination coverage, as reported for Germany.
Scenario 1 remains unchanged in all analyses presented by these graphs. Scenario 2 assumes that annual vaccination of children up to a given
maximum age (see numbers on the right hand side) is recommended in Germany, starting in 2012. In scenario 2, the vaccination coverage of
children from 2 years up to the recommended age is increased in three annual steps, starting from the baseline value and finally reaching the
coverage given on the horizontal axis; the vaccination coverage of children in other age groups and of adults is kept at the baseline value
(which is also used in scenario 1). (a) TIV is used for all children and adults in scenario 2; (b) LAIV is used for all children from 2 years up to the
recommended maximum age of childhood vaccination, and TIV is used for all others; (c) LAIV is used for all children from 2 years up to the
recommended maximum age of childhood vaccination (with increasing coverage) and for all older children up to 17 years (with constant
coverage); TIV is used for all others.
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changes are made in scenario 2, whereas scenario 1
always remains unchanged.
On the vertical axes, Figure 6 shows how many symp-
tomatic influenza cases would be prevented by the vac-
cination strategy described in scenario 2 as compared to
scenario 1 during the 10 year evaluation period. The
maximum number of prevented symptomatic cases is
always reached if 95% of all children up to 17 years of
age are vaccinated annually. In Figure 6a (only TIV vac-
cination), scenario 2 would prevent 12.7 million more
symptomatic cases in 10 years than scenario 1 would; in
Figure 6b (LAIV and TIV vaccination) and 6c (only
LAIV vaccination for children from 2 years of age), sce-
nario 2 would prevent 21.5 million more symptomatic
cases in 10 years than scenario 1 would. The vaccination
strategy of using only LAIV (Figure 6b) in older children
can only differ from the mixed strategy (Figure 6c) if the
maximum vaccination age is below 17 years. In that
case, more cases are prevented by the “only LAIV” strat-
egy than by the mixed strategy, especially, if the annual
vaccination coverage is low. Both LAIV strategies pre-
vent more symptomatic cases than the strategy which
uses only TIV, most noticeably for low annual vaccin-
ation coverage.
We also developed an alternative model that totally ig-
nores herd immunity effects. When using this model,
the overall reduction in symptomatic cases induced by
LAIV drops from 40% to 10%. This shows that the indir-
ect protection accounts for a large part of the total
benefit.Discussion
We have presented the results of several simulations
which were produced by a dynamic transmission model
described by more than 4,000 differential equations.
Even though our model considers the most important
demographic and epidemiologic features of seasonal in-
fluenza transmission, every model – irrespective of its
complexity – must be regarded as a gross simplification
of reality.Below we discuss our methodological decisions. Our
model considers age-dependent contact patterns, but
does not consider spatial or social structures. The model
assumes that the frequency of contacts between individ-
uals only depends on their age. We use the age distribu-
tion for Germany with birth rates consistent with
published data and age-dependent mortality rates, but
we ignore changes of the population caused by migra-
tion. We update the age of individuals only once every
year after the end of summer, as is done in other models
of influenza transmission and vaccination [21,37].
In our vaccination model, age-dependent fractions of
the population are either vaccinated with TIV or with
LAIV during October and November. However, we do
not keep track of who has received which type of vac-
cine in previous years or who experienced an infection
before vaccination. Consequently, we apply vaccinations
independently of each other and use average values for
the age-dependent vaccine efficacy which does not con-
sider pre-existing immunity. As LAIV vaccination has
not been approved for children below 2 years of age,
they only receive TIV in all simulation scenarios. Due to
the classification of individuals in 1-year age classes and
because of the annual ageing step at the end of summer,
we omit vaccination of newborn children between six
and 12 months of age in both simulation scenarios,
which resulted in a slight underestimation of the benefi-
cial effect of childhood vaccination.
The variability of the viral strains over time is consid-
ered in our model only indirectly by assuming that it
takes on average six years until an individual can be in-
fected again with influenza A; protection against influ-
enza B lasts on average twelve years [21], as B strains
tend to be more stable than A strains. We assume that
66.9% of infections lead to symptoms, but – due to the
lack of solid information – we have not implemented a
dynamically changing fraction of partially immune indi-
viduals who may have a milder course of disease or a re-
duced contagiousness.
Our simulation results show the typical seasonal waves
which usually peak at the end of February (Figure 3).
Without additional childhood vaccination, our simulations
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Germany (Figure 4). About one third of all simulated
symptomatic cases in scenario 1 (35.6%) are caused by
influenza B.
The conservative character of our approach is reflected
by the number of simulated medical consultations being
lower than the data published by the RKI (Figure 2). Solid
data on the age-specific infection incidence in Germany
are scarce, but we were able to compare our simulation re-
sults to the infection incidence among young adults [33],
obtaining a good concordance. The same applies to the
clinical attack rate in children when compared to esti-
mates from international studies. Adding the agreement of
our double-coding results, this indicates that our model is
reliable and trustworthy.
Some simulation parameters are not precisely known,
while others may change from season to season due to
changes in the viral strains. We have addressed this inse-
curity by various sensitivity analyses. As our main
outcome is the difference between the number of symp-
tomatic cases in the scenarios with and without add-
itional childhood vaccination, the fraction of infections
which leads to symptoms is one of the most influential
parameters (Figure 5). Varying the duration of vaccine-
induced protection of LAIV has also a large impact on
the results. Hence, there is a great need for future
research on this subject.
Another important parameter is the duration of im-
munity after the infection (most notably for influenza A
which causes two thirds of cases): if immunity lasts lon-
ger, fewer cases occur and fewer cases can be prevented
by childhood vaccination. For the same reason, the basic
reproduction number R0 which determines the transmis-
sibility of influenza also strongly influences the results.
As changes in the basic reproduction number can result
in bi-annual cycles with consecutive large and small sea-
sonal waves, it is somewhat difficult to predict whether a
modification of the value of R0 leads to larger or smaller
numbers of prevented cases.
Various simulation studies have assessed the clinical and
economic implications of childhood vaccination against
seasonal influenza in different settings. These evaluations
have shown that influenza vaccination of children is cost-
effective and may even be cost-saving [38,39]. However,
most of the previous simulation studies have lacked con-
sideration of herd immunity effects. Results of recently
published studies based on dynamic transmission models
underline the importance of taking indirect protection
(herd immunity) benefits to the community into account
[37,40]. Our model results confirm these findings.
Conclusions
Paediatric influenza represents a substantial burden to
public health. Children have high influenza illness ratesand transmit the disease within the community, posing
considerable health and financial consequences to the
society. In this paper, we evaluated the epidemiological
impact of the implementation of an additional LAIV-
based childhood influenza immunisation programme in
Germany. Our results demonstrate that vaccinating
children 2–17 years of age is likely associated with a
significant reduction in the burden of paediatric influ-
enza. Furthermore, annual routine childhood vaccination
against seasonal influenza is expected to decrease the in-
cidence of influenza among adults and older people due
to indirect effects of herd protection. These results will
be used to inform a cost-effectiveness analysis of univer-
sal childhood influenza vaccination in Germany.
In summary, our model provides data supporting the
implementation of a paediatric influenza immunisation
programme in Germany. Due to the high efficacy and
the easy and painless route of administration, the use of
LAIV in children aged 2–17 years could be an important
part of such a programme.Additional file
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